Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2020 Jul 6;21:288. doi: 10.1186/s12859-020-03633-z

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2020

Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

PMC Copyright notice

Fig. 6 — PDXGEM prediction for response to Cetuximab in metastatic colorectal cancer patient. a Distribution of PDXGEM scores (y-axis) is compared between metastatic colorectal cancer patients with complete response (CR) or partial response (PR) and those with stable of disease (SD) or progressive disease (PD) after treatment with cetuximab. Blue and red dots are subjects with or without positive epidermal growth factor receptor (EGFR) expression, respectively. b PDXGEM scores stratified by KRAS mutation status. c Kaplan-Meier curves of overall survival in metastatic colorectal cancer patients who did not receive cetuximab